✦ LIBER ✦

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

✍ Scribed by Schønnemann, K R; Jensen, H A; Yilmaz, M; Jensen, B V; Larsen, O; Pfeiffer, P

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of capecitabine plus 3-

✍ Park, Y H; Kim, B-S; Ryoo, B-Y; Yang, S H 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 104 KB

Phase II study of capecitabine plus oxal

✍ Yu Hong Li; Hui Yan Luo; Feng Hua Wang; Zhi Qiang Wang; Miao Zhen Qiu; Yan Xia S 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 234 KB

Phase II study of capecitabine and cispl

✍ Kang, H J; Chang, H M; Kim, T W; Ryu, M-H; Sohn, H J; Yook, J H; Oh, S T; Kim, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 102 KB

A multiple-center phase II study of week

✍ Jen-Shi Chen; Yen-Yang Chen; Jen-Sheng Huang; Kun-Yun Yeh; Ping-Tsung Chen; Wen- 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 181 KB

Phase II study of capecitabine and mitom

✍ Rao, S; Cunningham, D; Price, T; Hill, M E; Ross, P J; Tebbutt, N; Norman, A R; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 92 KB

Phase I/II study of a combination of doc

✍ Yoon-Koo Kang; Min-Hee Ryu; Changhoon Yoo; Heung-Moon Chang; Jeong Hwan Yook; Su 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 334 KB